Get the Stockscreener App
7.45
9.40%
0.64
Pre-market:
7.51
0.06
+0.81%
Adaptive Biotechnologies Corp stock is traded at $7.45, with a volume of 1.76M.
It is up +9.40% in the last 24 hours and up +16.59% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$6.81
Open:
$6.95
24h Volume:
1.76M
Relative Volume:
1.42
Market Cap:
$1.10B
Revenue:
$177.28M
Net Income/Loss:
$-195.24M
P/E Ratio:
-5.5597
EPS:
-1.34
Net Cash Flow:
$-114.54M
1W Performance:
+22.73%
1M Performance:
+16.59%
6M Performance:
+84.41%
1Y Performance:
+80.83%
1-Day Range:
$6.95
$7.50
1-Week Range:
$6.34
$7.50
52-Week Range:
$2.28
$7.50
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
7.45 | 1.10B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Adaptive Biotechnologies stock hits 52-week high at $7.47 - Investing.com India
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Drops -1.59 Percent In Recent Trading, What Questions Do You Have? – Stocks Register - Stocks Register
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by JPMorgan Chase & Co. - Defense World
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock? - MSN
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 17.6%Time to Buy? - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5%What's Next? - MarketBeat
Adaptive Biotechnologies and NeoGenomics partner to expand access to disease monitoring for blood cancer patients - Seeking Alpha
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients - Yahoo Finance
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Acquired by Barclays PLC - MarketBeat
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025 - Benzinga
Adaptive Biotechnologies: 1Q Earnings Snapshot -May 12, 2020 at 04:27 pm EDT - Marketscreener.com
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - Benzinga
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025 - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at $7.08 By Investing.com - Investing.com Australia
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 12-Month HighStill a Buy? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at $7.08 - Investing.com
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 7.3% HigherHere's Why - MarketBeat
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Geode Capital Management LLC Sells 20,450 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Drop in Short Interest - MarketBeat
Seattle InnoAdaptive's royalty financing I Changes at Tanium - The Business Journals
Barclays PLC Has $1.18 Million Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock Holdings Lifted by Barclays PLC - MarketBeat
Adaptive Biotechnologies Corporation Provides MRD Business Revenue Guidance for the Full Year 2024 - Marketscreener.com
State Street Corp Acquires 48,885 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Jane Street Group LLC - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) vs. Moderna (NASDAQ:MRNA) Financial Comparison - Defense World
BTIG Research Raises Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $9.00 - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.6%What's Next? - MarketBeat
Are Medical Stocks Lagging BellRing Brands (BRBR) This Year? - Yahoo Finance
Charles Schwab Investment Management Inc. Purchases 10,262 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
ARK Invest Shakes Up Portfolios! Major Tech Sell-Off and Biotech Bets! - Jomfruland.net
Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
ADPT stock touches 52-week high at $6.71 amid robust gains By Investing.com - Investing.com South Africa
ADPT stock touches 52-week high at $6.71 amid robust gains - Investing.com
Jacobs Levy Equity Management Inc. Makes New $736,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Point72 Asset Management L.P. Makes New $2.54 Million Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Pier Capital LLC Grows Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions - Yahoo Finance
ADPT (Adaptive Biotechnologies) 10-Year Sortino Ratio : N/A (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) 1-Year Sortino Ratio : 1.18 (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register
Adaptive Biotechnologies (STU:1HM) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Matrix Capital Management Company LP Sells 10,922,590 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (FRA:1HM) Earnings Yield (Joel Gre - GuruFocus.com
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting - Yahoo Finance
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):